宫颈癌 肺转移 努力学习中 请版主指点

下午没事看论文，找到一个重磅的，GOG2015发的：

Int J Gynecol Cancer. 2014 Jun;24(5):916-22. doi: 10.1097/IGC.0b013e3182a80aec.
Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.

Chiantera V1, Rossi M, De Iaco P, Koehler C, Marnitz S, Ferrandina G, Legge F, Parazzini F, Scambia G, Schneider A, Vercellino GF.
Author information
1
*Department of Gynecology and Gynecological Oncology, Campus Mitte (CCM) and Campus Benjamin Franklin (CBF), Charitè University Berlin, Berlin, Germany; †Gynecologic Oncology Unit, S. Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; ‡Department of Radiooncology, Campus Mitte (CCM) and Campus Virchow (CVK), Charitè University Berlin, Berlin, Germany; §Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Rome, Italy; ∥Università di Milano, Fondazione Policlinico Milano, Milan, Italy; and ¶Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Campobasso, Italy.
Abstract
OBJECTIVE:
Evaluate the survival of patients who underwent pelvic exenteration (PE) with curative intent for primary persistent or recurrent cervical cancer.
METHODS:
We retrospectively investigated 167 consecutive patients, referred to the gynecological oncology units of 4 centers in Germany or Italy, who underwent PE. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until last follow-up or death.
RESULTS:
The median age was 51 years. Twenty-seven patients (16.2%) underwent PE owing to advanced primary tumors (group A), 34 patients (20.4%) underwent PE owing to persistent cancer after chemotherapy or chemoradiation (group B), and 106 patients (63.4%) underwent PE owing to recurrence (group C). The prevalent histologic type was squamous cell cancer. A complete tumor resection (R0), was achieved in 121 patients (72.5%). Forty-nine patients (29.3%) had pelvic lymph node metastases and 44 patients (26.3%) had pelvic sidewall involvement. Overall survival at the end of the study was 40.7%. The cumulative 5-year overall survival for the entire cohort was 38%. Resection margins, pelvic lymph node state, and sidewall involvement were independent prognostic factors in multivariate analysis.
CONCLUSION:
Pelvic exenteration is a valid therapeutic option for patients with locally advanced primary persistent or recurrent cervical cancer, with a long-term survival in 40% of the patients.

上面的文献，医学专业翻译说不是廓清术，问了几个教授说是廓清术。
哪位看客帮忙再论证下是不是盆腔廓清术？

确认了PE是盆腔廓清术，样本量167例，5年生存率38%，来自GOG的数据。

独孤八戒 发表于 2017-12-4 10:27

                               
登录/注册后可看大图

确认了PE是盆腔廓清术，样本量167例，5年生存率38%，来自GOG的数据。

对宫颈癌，这个方案是一个巨大的进步。

忙一天终于搞定了机构愿意按照我提供的论文方式做19个miRNA的检测，测这个的目的是  要比肿瘤指标scc   211更提前的发现问题更早的预警。帖子前面提到过miRNA205就是其中一项。先把这19个搞定，然后想办法做外周血HPV E6E7的检测，检测方式有两种，目前还没想好用哪种。最后再结合cc常见的肿瘤突变基因检测ctDNA。
这样一来，DNA  RNA  蛋白三种检测结合起来，应该会有意想不到的效果吧？ 鬼知道，边走边看。
@猫版   咱就此问题探讨下？

要多几个样本比较好。

最后回答一下不明真相的病友们普遍关心的问题，我夫人活的很好，不忌口不服用中药，同时很多最新方案正在跟踪,争取落实。
提醒广大病友们，注意保护好自己的各项检查、复查报告和数据，不要见人就给。抗癌路上全是坑，请睁大眼睛，多学习多研究是为正道。我加了那么多群,最不干净的就是宫颈群.没有之一.
这个帖子我会一直保持更新，让更多的病友看到。
@猫版   以上内容别删，为了让广大病友不被误导，不要删。